Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Guadecitabine (SGI-110) 治疗中度或高度风险骨髓增生异常综合征患者：一项多中心、开放标签、随机、1/2 期临床试验的 2 期结果
期刊:Lancet Haematology
影响因子:15.4
doi:10.1016/S2352-3026(19)30029-8
Guillermo Garcia-Manero, Gail Roboz, Katherine Walsh, Hagop Kantarjian, Ellen Ritchie, Patricia Kropf, Casey O'Connell, Raoul Tibes, Scott Lunin, Todd Rosenblat, Karen Yee, Wendy Stock, Elizabeth Griffiths, Joseph Mace, Nikolai Podoltsev, Jesus Berdeja, Elias Jabbour, Jean-Pierre J Issa, Yong Hao, H
